title: Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic.
abstract: Alzheimer's disease is one of the most significant healthcare problems today, with a dire need for effective treatment. Identifying subtypes of Alzheimer's disease may aid in the development of therapeutics, and recently three different subtypes have been described: type 1 (inflammatory), type 2 (non-inflammatory or atrophic), and type 3 (cortical). Here I report that type 3 Alzheimer's disease is the result of exposure to specific toxins, and is most commonly inhalational (IAD), a phenotypic manifestation of chronic inflammatory response syndrome (CIRS), due to biotoxins such as mycotoxins. The appropriate recognition of IAD as a potentially important pathogenetic condition in patients with cognitive decline offers the opportunity for successful treatment of a large number of patients whose current prognoses, in the absence of accurate diagnosis, are grave.
authors: Easton Laboratories for Neurodegenerative Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095, USA.|Buck Institute for Research on Aging, Novato, CA 94945, USA.
authors: Dale E
authors: DE
authors: Bredesen
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology / Q000209:etiology*; D004781:Environmental Exposure / Q000009:adverse effects*; D004787:Environmental Pollution / Q000009:adverse effects; D058872:Epidemics; D005260:Female; D006801:Humans; D007249:Inflammation / Q000382:microbiology; D001239:Inhalation; D008297:Male; D008875:Middle Aged; D009183:Mycotoxins / Q000009:adverse effects*
chemical_list: D009183:Mycotoxins
keywords: biomarkers; biotoxins; chronic inflammatory response syndrome; cognition; dementia; mycotoxins; neurodegeneration